Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did.
A follow-up question about four-week escalation interval that I did not know to ask the first time.
The earlier thread answered what I asked. What I should have asked is below, and I think it is the one that matters.
This follows the opening post rather than contradicting it.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
I have written this out at length because the short version keeps being misread.
Two things can be true about four-week escalation interval at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.
I keep a log for four-week escalation interval specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
Two people can read the same figure differently here and both be reasonable.
Picking up post #5: that is the part I would want checked first.
There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".
One of those cases where knowing the mechanism does not help the decision.
Where I have landed on four-week escalation interval, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
The confident answers on four-week escalation interval and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
I had written a reply contradicting post #8 and deleted it. Here is what survived.
Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
Adding the measurement that post #10 says would settle it.
Nothing here is medical advice, and a titration question is one of the few where a prescriber can genuinely answer in a minute what a thread will take a week to circle.
If it helps: the failure mode here is usually boring rather than dramatic.
Same experience here, different supplier, so it is at least not unique to one of them.
Four-week escalation interval has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Coming back to post #12, because the follow-up matters more than the original answer.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
I have changed my mind on this once already, so take it as current rather than settled.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
On four-week escalation interval, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Adding a data point of agreement rather than a data point.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
That is the shape of it. The detail is where I would expect to be corrected.
Summarising the four-week escalation interval thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Where I part company with post #21, and it is a narrow parting.
The most useful reply I ever got about four-week escalation interval was a request to state my units. It sounds like pedantry and it has saved me twice.
Half steps are arithmetically simple and pharmacologically unstudied. They are not dangerous in any obvious way and they are also not what the evidence describes, and both halves of that should be said.
Checked the four-week escalation interval claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
Building on post #25 rather than restating it.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
If that reads as pedantic, it is, and it has saved me twice.
Worth separating two things that post #25 runs together.
I read the earlier replies on four-week escalation interval twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
This follows post #29 rather than contradicting it.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.